VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development PlanScientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial de-risking of the development path for this novel therapeutic modality
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® PipelineArdigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs)
VERAXA Biotech Appoints Rick Austin as Chief Scientific OfficerIndustry Veteran to Support Acceleration of Key Pipeline Projects and Novel BiTAC™ Antibody Formats Towards Clinical Studies
